More recently, treatment of individuals diagnosed with AD with a nutraceutical formulation containing SAM (folate, alpha-tocopherol, B12, SAM, N-acetyl cysteine, acetyl-L-carnitine) under open-label conditions for 12 months resulted in the prevention of cognitive decline56.This study represents the first evaluation of SAM cognitive effects in an AD preclinical model triggered by a single transgene (FAD mutated APP) in the absence of exacerbated Aβ production caused by dietary deficiencies. Here, APP is linked to Alzheimer disease.